Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Completed · Phase 4

Conditions studied: COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection

In brief

To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine

Key facts

Study ID
NCT06633835
Run by
Novavax
People needed
660
Starts
2024-09-19
Expected to finish
2025-06-30
Last updated by the study team
2026-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.